Professor Dr. Michael Hershfield

Biography

Michael Steven Hershfield is a Professor in the Departments of Medicine and Biochemistry at Duke University. His research focuses on the molecular basis of inherited disorders related to purine metabolism, particularly combined immunodeficiency diseases caused by deficiencies in adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP). For over three decades, he has investigated the biochemical mechanisms responsible for immune deficiencies linked to these disorders, contributing to the clinical development of polyethylene glycol-modified adenosine deaminase (PEG-ADA) replacement therapy, which received FDA approval in 1990. His work includes collaborative studies using ADA knockout mice to understand the interaction of human ADA with the CD26/Dipeptidyl Peptidase IV complex. His findings have been significant in shaping the understanding and treatment of ADA deficiency and related metabolic diseases. In addition to his research on immune deficiencies, he has engaged in translational research aimed at developing PEGylated recombinant urate oxidase for treating refractory gout. Hershfield's extensive publication record includes major textbook chapters and reviews in the field, and he has served as a key resource in diagnosing and managing ADA PNP deficiency, impacting patients across 20 countries. His ongoing research involves examining the immune response to PEG-based therapies and optimizing dosing regimens for gout treatment. He has been awarded numerous grants and has held various academic appointments during his career.

Research Interests